News and updates

WHO empfiehlt einmalige HPV-Impfung (xrender/Shutterstock.com)

The World Health Organisation (WHO) recommends the one-dose HPV vaccination of girls and women up to 21 years of age instead of the current two-time vaccination. The WHO wants to increase the vaccination rate in the fight against cervical cancer. In principle, we welcome this plan, but we also have reservations regarding the new recommendation[1]. […]

EUROGIN2022-oncgnostics

The EUROGIN is THE event for our current application areas and most of the experts were in Düsseldorf. So were we! With four presentations oncgnostics participated in the scientific discourse at the International multidisciplinary HPV Congress. The congress was again a great opportunity for us to make new contacts, maintain existing partnerships and exchange ideas […]

The business magazine Capital selected Germany’s most innovative companies for the third time. Oncgnostics GmbH made it into the selection. The biotech company scored particularly well in the evaluation criterion of innovation areas. For the third time, Capital, together with the market research institute Statista, determined Germany’s most innovative companies. For this purpose, they brought […]

10 years ago a small, very motivated team founded the oncgnostics GmbH to improve cervical cancer screening. Since then, oncgnostics GmbH has been growing and with it the number of its employees. On the occasion of the anniversary, it is time to share the experiences of the employees of the biotech company. 10 years of […]

team of oncgnostics celebrates 10th anniversary

The company oncgnostics GmbH, founded in 2012, already launched its first product in 2015: the diagnostic test for cervical cancer “GynTect”. This is now sold in over ten countries in Europe and Asia. In addition, oncgnostics conducts research in the field of diagnostics for head and neck cancer. The company is growing steadily and has […]

Dr. Carolin Dippmann and Daria Meyer from our research and development team work, among other things, with the “third-generation sequencing” method. With the help of this technology, they are examining DNA (deoxyribonucleic acid) from tumors much more precisely than was previously possible. The method has enormous advantages: epigenetic changes in the DNA, specifically DNA methylation […]

Eindrücke vom Jahr 2021 bei der oncgnostics GmbH

We look back on the milestones of 2021 – and forward to upcoming projects. In May, we moved the entire company within Jena, thus gaining space for more office workspace and a better layout of the labs. Recently, our team grew by one colleague, so that we are now 18 people. One of the reasons […]

Every year, about 7,300 women in Germany are diagnosed with ovarian cancer (ovarian carcinoma), and more than 5,000 die of the consequences. This means that one in 72 women will be diagnosed with ovarian cancer at some point in their lives. In those affected, cells on one or both ovaries change malignantly and begin to […]

As a biotechnology company, we have been researching cancer diagnostics on a molecular basis since 2012. We deal with epigenetic markers, which help us to recognise cancers, such as cervical cancer, in their preliminary stages. In this article, we explain the terms “epigenetics” and “epigenetic marker”. Epigenetics – what is it? Epigenetics deals with the […]

A large proportion of women who develop cervical cancer in high-income countries such as Germany do not regularly attend screening. This is particularly alarming, as cancer screenings have become much less frequent since the onset of the corona pandemic. A study by Hannover Medical School and the biotechnology company oncgnostics GmbH is testing self-tests as […]